• Home
  • News

Sichenzia Ross Ference LLP Represents BriaCell Therapeutics Corp. in Nasdaq listing and $25 Million Public Offering 

briacell therapeutics

Press Release – New York, NY – February 26, 2021 – Sichenzia Ross Ference LLP today announced that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSXV: BCT), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, in a public offering of 4,852,353 common units at a public offering price of $4.25 per unit, consisting of one share of common stock and one warrant to purchase one share of common stock, and 1,030,000 pre-funded units at a public offering price of $4.24 per unit, consisting of one pre-funded common stock purchase warrant and one warrant.  The aggregate gross proceeds were approximately $25.0 million. The common shares and warrants trade on the Nasdaq Capital Market under the symbols “BCTX” and “BCTXW”, respectively.  

ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.  

A registration statement on Form F-1 (File No. 333-234292) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on February 23, 2021.

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Avital Perlman, and Arthur Marcus and law clerk Zachary Weiss.

Sichenzia Ross Ference LLP